Physician profile
Daniel J Coden
NPI 1942317508
$7,629.43
in general payments reported to CMS, 2019-2025
17 companies · $630 in 2025
The $630 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,756 · 2020: $170 · 2021: $329 · 2022: $276 · 2023: $4,439 · 2024: $30.02 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,400 · Food and Beverage: $699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,400.00 |
| Food and Beverage | $698.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $4,697.91 | 2019-2025 | Clareon Panoptix Pro, Clareon |
| Biotissue Holdings INC. | $1,207.94 | 2019 | |
| Horizon Therapeutics Plc | $367.64 | 2019-2023 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $343.90 | 2019-2025 | Tecnis Simplicity |
| Allergan, INC. | $262.96 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $215.95 | 2025 | Xiidra, Miebo, Envista Mx60 Iol |
| Abbvie INC. | $115.09 | 2022-2025 | |
| Carl Zeiss Meditec, INC. | $91.60 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $90.83 | 2019-2020 | |
| Kala Pharmaceuticals, INC. | $66.61 | 2019-2021 | |
| Amgen INC. | $44.82 | 2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $29.85 | 2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $21.50 | 2020 | |
| Akorn, INC. | $20.05 | 2020 | |
| Rxsight INC | $18.50 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $18.31 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Coden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.